These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21744523)

  • 41. [Catecholamines use in patients with heart failure].
    Iino K; Ito H
    Nihon Rinsho; 2007 May; 65 Suppl 5():30-3. PubMed ID: 17571362
    [No Abstract]   [Full Text] [Related]  

  • 42. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.
    Bayram M; De Luca L; Massie MB; Gheorghiade M
    Am J Cardiol; 2005 Sep; 96(6A):47G-58G. PubMed ID: 16181823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of temperature on the positive inotropic effect of levosimendan, dobutamine and milrinone.
    Rieg AD; Schroth SC; Grottke O; Hein M; Ackermann D; Rossaint R; Schälte G
    Eur J Anaesthesiol; 2009 Nov; 26(11):946-53. PubMed ID: 19687740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure.
    Jennings DL; Thompson ML
    Ann Pharmacother; 2009 Nov; 43(11):1872-6. PubMed ID: 19789358
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Extended release oral milrinone as an adjunct to heart failure therapy.
    Nanayakkara S; Bergin P; Mak V; Crannitch K; Kaye DM
    Intern Med J; 2017 Aug; 47(8):973-974. PubMed ID: 28782207
    [No Abstract]   [Full Text] [Related]  

  • 46. Infusion therapy with milrinone in the home care setting for patients who have advanced heart failure.
    Boger JE; DeLuca SL; Watkins DF; Vershave KK; Thomley AM
    J Intraven Nurs; 1997; 20(3):148-54. PubMed ID: 9214927
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral heart failure medications: an update for home health clinicians.
    Cheek DJ; Sherrod MM; Graulty R; Hawkins J
    Home Healthc Nurse; 2008; 26(10):600-11; quiz 612-3. PubMed ID: 19001915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new direction for dobutamine.
    Sohl LL; Applefeld MM
    Nursing; 1990 Oct; 20(10):42-3. PubMed ID: 2216089
    [No Abstract]   [Full Text] [Related]  

  • 49. [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
    Meissner A; Schmelzle T; Simon R
    Z Kardiol; 1996 Nov; 85(11):839-46. PubMed ID: 9064946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.
    Pflugfelder PW; O'Neill BJ; Ogilvie RI; Beanlands DS; Tanser PH; Tihal H; Mizgala HF; Fitchett DH; Kostuk WJ
    Can J Cardiol; 1991; 7(1):5-10. PubMed ID: 2025794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discussion.
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2323-4. PubMed ID: 25175955
    [No Abstract]   [Full Text] [Related]  

  • 53. Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good.
    Varriale P; Ramaprasad S
    Pharmacotherapy; 1997; 17(2):371-4. PubMed ID: 9085331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extended Release Oral Milrinone, CRD-102, for Advanced Heart Failure.
    Nanayakkara S; Mak V; Crannitch K; Byrne M; Kaye DM
    Am J Cardiol; 2018 Sep; 122(6):1017-1020. PubMed ID: 30064857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic heart failure and the quality of life.
    Pritzker MR
    N Engl J Med; 1999 May; 340(19):1511; author reply 1512. PubMed ID: 10328720
    [No Abstract]   [Full Text] [Related]  

  • 56. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure.
    Herweg B; Ilercil A; Cutro R; Dewhurst R; Krishnan S; Weston M; Barold SS
    Am J Cardiol; 2007 Jul; 100(1):90-3. PubMed ID: 17599447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The effects of intravenous milrinone for the patient undergoing CABG].
    Yasuda F; Shimono T; Cruz BP; Komada T; Tokui T; Onoda K; Tanaka K; Shimpo H; Yada I; Okuda M; Utsunomiya H; Maruyama K
    Kyobu Geka; 2000 Feb; 53(2):117-21. PubMed ID: 10667021
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times.
    Assad-Kottner C; Chen D; Jahanyar J; Cordova F; Summers N; Loebe M; Merla R; Youker K; Torre-Amione G
    J Card Fail; 2008 Dec; 14(10):839-43. PubMed ID: 19041047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tailored treatment for heart failure.
    Shibata M; Perez de Arenaza D
    Lancet; 2000 Aug; 356(9230):686. PubMed ID: 10968472
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.